GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Other Income (Expense)

Abionyx Pharma (XPAR:ABNX) Other Income (Expense) : €-0.29 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Other Income (Expense)?

Abionyx Pharma's other income expense for the Abionyx Pharma's pretax income for the six months ended in Dec. 2023 was €-0.16 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.29 Mil.

Abionyx Pharma Other Income (Expense) Historical Data

The historical data trend for Abionyx Pharma's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Other Income (Expense) Chart

Abionyx Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.05 -0.10 -0.09 -0.29

Abionyx Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.09 - -0.13 -0.16

Abionyx Pharma Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma  (XPAR:ABNX) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Abionyx Pharma (XPAR:ABNX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Other Income (Expense)
Comparable Companies
XPAR:ALACT XPAR:ALGEN XPAR:GNRO XPAR:ALCLS XPAR:PHXM XPAR:ALVIO XPAR:ALDVI XPAR:SIGHT XPAR:ALCOX XPAR:POXEL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
609:Germany
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Website
https://www.abionyx.com
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines